Industry News

Biotech council: Biologics, innovation need protection from generics

President Obama and Congressional leaders have made a clear case for reform on the U.S. health care system, and we fully support a reform that would improve quality of care and controlling costs. President Obama and draft proposals in Congress have provided us with hope in these uncertain times, and we appreciate the strong initiative he and congressional leaders have demonstrated in attempting to reach consensus expeditiously. Members of the biotechnology industry — from early-stage startup companies to global biotech leaders — have significant concerns about one particular aspect of the health care reform effort, a pathway to biosimilars.